Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,758 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Platinum Based Chemotherapy Clear all

Conditions: Squamous Cell Carcinoma of the Penis, Usual Type
Interventions: ILND - Inguinal Lymph Node Dissection, Paclitaxel, Ifosfamide, Cisplatin, Intensity modulated radiation treatment (IMRT), Prophylactic PLND - pelvic lymph node dissection; Procedure · Drug · Radiation
Lead sponsor: Institute of Cancer Research, United Kingdom; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix
Interventions: Telaglenastat, Radiation treatment, Cisplatin; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Extensive-stage Small-cell Lung Cancer
Interventions: Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy; Drug · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastric Cancer
Interventions: Capecitabine, Cisplatin, Herceptin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: La Jolla, California • Los Angeles, California • Whittier, California + 5 more

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: AZD1775, Cisplatin, Intensity Modulated Radiotherapy Treatments; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Interventions: Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia

Conditions: Ovarian Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chemotherapy-induced Cognitive Impairment
Interventions: Neurocognitive assessments; Behavioral
Lead sponsor: Rachel Miller; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Esophageal Cancer
Interventions: bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy; Biological · Drug · Genetic + 3 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Small Cell Lung Carcinoma
Interventions: Ipilimumab, Placebo matching Ipilimumab, Etoposide, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 42
States / cities: Hot Springs, Arkansas • Auburn, California • La Jolla, California + 34 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbus, Ohio

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Cisplatin, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gastrointestinal Cancer
Interventions: Mitomycin C, Cisplatin, Sodium Thiosulfate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: Fludarabine, Novantrone, Decadron, Rituximab, Interferon, Doxorubicin, Vincristine, Bleomycin, Cyclophosphamide, Etoposide, Cisplatin, Ara-C, Methyl-Prednisolone, Procarbazine, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 76 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Toripalimab-tpzi, Cisplatin, Docetaxel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8
Interventions: Cisplatin, External Beam Radiation Therapy, Nelfinavir; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cisplatin, fenretinide, paclitaxel; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Head and Neck Neoplasms
Interventions: Pembrolizumab, Placebo, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy, Standard Fractionation (SFX) Radiotherapy; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 24
States / cities: Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more

Conditions: Lung Cancer
Interventions: carboplatin, cisplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 13
States / cities: Atlanta, Georgia • Des Moines, Iowa • Papillion, Nebraska + 8 more

Conditions: Head and Neck Cancer
Interventions: IMC-A12 (cixutumumab), cetuximab (Erbitux ®); Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 14
States / cities: Orange, California • Miami, Florida • Orlando, Florida + 11 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Head and Neck
Interventions: nab-paclitaxel, Cisplatin, Carboplatin, Cetuximab; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 5
States / cities: Little Rock, Arkansas • Jackson, Mississippi • St Louis, Missouri + 2 more

Conditions: Cervical Cancer
Interventions: Nivolumab induction, Cisplatin, Radiation, Nivolumab with chemoradiation, Nivolumab maintenance; Drug · Radiation
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Esophageal Cancer
Interventions: Cisplatin, Irinotecan, Celecoxib, Radiation Therapy, Esophagectomy; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: NSCLC
Interventions: Doxorubicin HCl Inhalation Solution, Docetaxel, Cisplatin; Drug
Lead sponsor: Zivena; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 6
States / cities: New Haven, Connecticut • Las Vegas, Nevada • The Bronx, New York + 2 more

Search by objective public record fields.

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Cost Utility Analysis in Recurrent Ovarian Cancer

Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck

Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

PDT For Induction Therapy For Head And Neck Cancer

Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)